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Abstract The transient treatment with parathyroid hormone 
(PTH) for 12 h, followed by its removal for 36 h, stimulated 
insulin-like growth factor-binding protein (IGFBP)-5 mRNA 
expression more strongly than the continuous treatment for 48 h 
in osteoblastic UMR-106 cells. The transient but not continuous 
treatment with A23187 also stimulated it. In contrast, 1,25-
dihydroxyvitamin D 3 stimulated it, irrespective of the treatment 
design. IGFBP-5 stimulated type-1 procollagen mRNA expres-
sion. The present study first indicated that the transient 
treatment with PTH more effectively stimulated IGFBP-5 
mRNA expression than its continuous treatment partly via an 
increase in intracellular calcium and suggested that IGFBP-5 
might be involved in the anabolic action of PTH in bone. 
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1. Introduction 
It is well known that parathyroid hormone (PTH) possesses 
a catabolic action in bone, but its anabolic action in bone has 
also been shown [1]. The previous studies [2,3] demonstrated 
that the intermittent administration of P T H to rats caused an 
increase in bone volume and stimulated bone formation. 
Clinical study [4] also revealed that the intermittent admin-
istration of P T H increased the bone mineral density in osteo-
porotic patients. Moreover, a previous in vitro study [5] re-
vealed that transient treatment with P T H increased the 
synthesis of type-1 collagen, whereas with continuous treat-
ment with P T H it decreased. Thus, intermittent treatment 
with PTH seems to promote anabolic action in bone. How-
ever, its mechanism has not been clearly defined. 
Insulin-like growth factor (IGF)-I is produced by osteo-
blasts and regulates bone formation in an autocrine and/or 
paracrine fashion [6,7]. Several IGF-binding proteins ( IGFBP) 
are also produced by osteoblasts [8]. Among these IGFBPs , 
IGFBP-5 stimulates osteoblast proliferation directly or indi-
rectly through IGF-I action [9,10]. Moreover, IGFBP-5 has a 
very strong affinity for hydroxyapatite [11], suggesting its im-
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por tant role in bone formation. Torring et al. [12] reported 
that P T H stimulated IGFBP-5 production in osteoblastic 
UMR-106 cells. It is, therefore, possible that the anabolic 
action of the intermittent treatment with PTH in vivo might 
be partly via its effect on IGFBP-5 production in osteoblasts. 
On the other hand, there has been evidence [13-15] that 1,25-
dihydroxyvitamin D 3 ( l ,25(OH) 2 D 3 ) , another important cal-
cium-regulating hormone, might stimulate bone formation 
partly via augmenting IGF-I activity. 
The present study was, therefore, performed to compare 
the effect of transient or continuous treatment with P T H or 
1,25 (OH) 2 D 3 on IGFBP-5 m R N A expression in UMR-106 
cells. 
2. Materials and methods 
2.1. Materials 
UMR-106 cells were the generous gift from Dr. T.J. Martin (Mel-
bourne, Australia). Human (h) PTH-(l-34) was purchased from Pep-
tide Institute Inc. (Osaka, Japan). l,25(OH)2Ü3 was kindly provided 
by Chugai Pharma Co. Ltd. (Shizuoka, Japan). N6,02,-dibutyryl ad-
enosine 3',5'-cyclic monophosphate (dbcAMP) and phorbol 12-myr-
istate 13-acetate (PMA) were purchased from Sigma Chemical Co. 
(St. Louis, MO), A23187 from Hoechst Japan Co. (Tokyo, Japan), 
and recombinant human IGF-I and recombinant human IGFBP-5 
from Cosmo Bio Co. (Tokyo, Japan). All other chemicals were of 
analytical grade. 
2.2. Cell culture 
UMR-106 cells were maintained in Dulbecco's modified Eagle me-
dium (DMEM) containing 10% fetal calf serum and penicillin G (100 
IU/ml) in 5% C02-95% air atmosphere at 37°C, as previously de-
scribed [16]. Cells were passed weekly, using 0.05% trypsin-0.02% 
EDTA solution. UMR-106 cells were cultured in 6-well plates. For 
the continuous treatment, these cells were incubated with each sub-
stance for 48 h. For the transient treatment, these cells were incubated 
with each substance for 12 h, the incubation medium was replaced by 
fresh medium without substance several times, and the cells were 
further incubated for 36 h. 
2.3. Northern hybridization 
The total RNA was extracted from cultured cells by means of the 
acid guanidinium thiocyanate-phenol-chloroform extraction method 
[17]. Twenty micrograms of total RNA was denatured, and run on 
a 1% agarose gel containing 2% formaldehyde, then transferred to a 
nitrocellulose membrane. This was hybridized to a 32P-labeled DNA 
prove overnight at 42°C. The hybridization probe was either the 6.0 
kb Stul-SacU-HindlU fragment of the rat IGFBP-5 cDNA which 
was kindly provided by Dr. Shunichi Shimazaki (The Whitter Insti-
tute, La Jolla, CA), or the 2.8 kb EcoRl fragment of a l gene of type-1 
procollagen, a gift from Dr. Kimura (Osaka University, Japan). Also, 
a 1.2 kb ß-actin cDNA was used as a reference. After hybridization, 
the filter was washed twice with 2X standard saline citrate (SSC) 
containing 0.5% sodium dodecyl sulfate (SDS), and subsequently 
twice with 0.1 X SSC containing 0.5% SDS at 58°C for 1 h. 
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Fig. 1. Effects of continuous or transient treatment with PTH on IGFBP-5 mRNA expression in osteoblastic UMR-106 cells. Total RNA was 
isolated from UMR-106 cells after the continuous (for 48 h, left side) or transient (for 12 h, followed by its removal for 36 h, right side) treat-
ment with indicated concentrations of hPTH-(l-34). The transferred RNA blots were hybridized first with 32P-labeled rat IGFBP-5 cDNA and 
visualized by autoradiography. The probe was eluted and the blot was rehybridized with 32P-labeled ß-actin cDNA. 
3. Results and discussion dose-dependently stimulated the expression of IGFBP-5 
mRNA in these cells, and the transient treatment with PTH 
First, we examined the effects of the transient or continuous was more potent to stimulate IGFBP-5 mRNA expression 
treatment with 10"11 M to 10"8 M hPTH-(l-34) on IGFBP-5 than the continuous one. The stimulation by PTH of 
mRNA expression in UMR-106 cells. As shown in Fig. 1, IGFBP-5 mRNA expression was compatible with the previous 
both transient and continuous treatments with hPTH-(l-34) evidence [12] that 24 h treatment with PTH increased IGFBP-
Fig. 2. Effects of transient or continuous treatment with IGF-I or IGF-II on IGFBP-5 mRNA expression in osteoblastic UMR-106 cells. The 
preparation and methods for RNA blotting were the same as Fig. 1. Before RNA extraction, UMR-106 cells were treated either transiently 
(for 12 h, followed by its removal for 36 h, left side) or continuously (for 48 h, right side) with 10~8 M hPTH-(l-34), 10 ng/ml IGF-I, or 10 
ng/ml IGF-II. 
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Fig. 3. Effects of transient or continuous treatment with second messenger analogues on IGFBP-5 mRNA expression in osteoblastic UMR-106 
cells. The preparation and methods for RNA blotting were the same as Fig. 1. Before RNA extraction, UMR-106 cells were treated transiently 
(for 12 h, followed by its removal for 36 h, left side) or continuously (for 48 h, right side) with 10~4 M dbcAMP, 10~6 M PMA, or 10~6 M 
A23187. 
5 production in UMR-106 cells, and Conover et al. [18] re-
ported that the 6 h treatment with PTH stimulated IGFBP-5 
mRNA expression more strongly than the 24 h treatment. 
However, the present study first demonstrated that transient 
treatment with PTH was more effective than continuous treat-
ment to stimulate IGFBP-5 mRNA expression. 
Linkhart et al. [19] reported that PTH stimulated IGF-I 
and IGF-II release from neonatal mouse calvaria. Moreover, 
PTH enhanced the transcript and polypeptide levels of IGF-I 
in osteoblast-enriched cultures from fetal rat bone [20]. Since 
IGF-I and IGF-II regulate the availability of IGFBP-5 in 
osteoblast-like cells [21], we also examined the effect of tran-
sient or continuous treatments with IGF-I and IGF-II on 
IGFBP-5 mRNA expression in UMR-106 cells. As shown in 
Fig. 2, the transient treatment with 10 ng/ml IGF-I stimulated 
the expression of IGFBP-5 mRNA in these cells, but the 
continuous treatment with it did not. In contrast, both tran-
sient and continuous treatments with 10 ng/ml IGF-II stimu-
lated the expression of IGFBP-5 mRNA in these cells and the 
former was less effective than the latter. Since the effect of 
IGF-I was similar with that of PTH in the present study, 
IGF-I might be partly related to the effect of PTH by the 
transient treatment in UMR-106 cells. 
There has been previous evidence that PTH possesses dual 
signal transduction systems, that is, cAMP-dependent protein 
kinase (PKA) and phospholipase C-coupled calcium/protein 
kinase C (Ca/PKC) [22]. Next, we examined the effect of the 
transient or continuous treatment with dbcAMP, a PKA ac-
Fig. 4. Effects of transient or continuous treatment with l,25(OH)2Ü3 on IGFBP-5 mRNA expression in osteoblastic UMR-106 cells. The prep-
aration and methods for RNA blotting were the same as Fig. 1. Before RNA extraction, UMR-106 cells were treated transiently (for 12 h, fol-
lowed by its removal for 36 h) or continuously (for 48 h) with 10-8 M l,25(OH)2Ü3. 
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Fig. 5. Effects of IGFBP-5 and IGF-I on procollagen mRNA ex-
pression in osteoblastic UMR-106 cells. The preparation and meth-
ods for RNA blotting were the same as Fig. 1. Before RNA extrac-
tion, UMR-106 cells were treated with 230 ng/ml IGFBP-5, or 10 
ng/ml IGF-I for 24 h. Lane 1, control; lane 2, IGFBP-5; lane 3, 
IGF-I. 
tivator, PMA, a PKC activator, and A23187 which is thought 
to mimic myoinositol 1,4,5-trisphosphate by increasing intra-
cellular calcium ([Ca2+];). As shown in Fig. 3, the transient 
treatment with 10~6 M A23187 stimulated the expression of 
IGFBP-5 mRNA in these cells, but the continuous treatment 
did not affect it. In contrast, both transient and continuous 
treatments with 10~4 M dbcAMP stimulated the expression of 
IGFBP-5 mRNA in UMR-106 cells, and the former was less 
effective than the latter. Neither transient nor continuous 
treatment with 10 - 6 M PMA affected it. These findings sug-
gest that an increase in [Ca2+]i would be partly involved in the 
stimulatory effect of transient PTH treatment on IGFBP-5 
mRNA expression in UMR-106 cells. 
l,25(OH)2D3 is also an important calcium-regulating hor-
mone and regulates IGFBPs secretion [14,23]. Schmid et al. 
[15] reported that the treatment with l,25(OH)2D3 for 24 h 
increased IGFBP-5 mRNA expression in cultured osteoblasts. 
We, therefore, examined the effect of the transient or contin-
uous treatment with l,25(OH)2D3 on IGFBP-5 mRNA ex-
pression and compared its effects with those of PTH in 
UMR-106 cells. As shown in Fig. 4, l,25(OH)2D3 stimulated 
the expression of IGFBP-5 mRNA expression in a concentra-
tion-dependent manner and the maximum effective concentra-
tion was 10~8 M. Both transient and continuous treatments 
with 10~8 M l,25(OH)2D3 stimulated the expression of 
IGFBP-5 mRNA in these cells, but the transient treatment 
with l,25(OH)2D3 was less effective than the continuous 
one, which was different from the action of PTH. 
The present study revealed that transient treatment with 
PTH caused a marked increase in mRNA expression of 
IGFBP-5, a stimulator IGF action, which was in concert 
with the stimulatory effect of intermittent PTH administration 
on bone mass in vivo [2-4]. Since there have also been several 
lines of evidence suggesting some role of IGFBP-5 in bone 
formation [9-11], the possibility was raised that IGFBP-5 
might be partly involved in the anabolic action of PTH in 
bone. Type-1 collagen, the most abundant protein in bone 
matrix produced by osteoblasts, is an important marker of 
bone formation. We, therefore, examined whether IGFBP-5 
would really increase the gene expression of type-1 procolla-
gen in UMR-106 cells. As shown in Fig. 5, recombinant 
IGFBP-5 as well as IGF-I stimulated the expression of type-
1 procollagen mRNA in these cells. Since there has been evi-
dence that IGFBP-5 potentiates IGF-I action [10], it seems 
likely that IGFBP-5 stimulated the gene expression of type-1 
procollagen through augmenting the action of endogenous 
IGF-I released from these cells. Alternatively, IGFBP-5 per 
se might stimulate it in a manner independent of IGF-I, as 
binding sites of IGFBP-5 have been reported to exist in os-
teoblasts [9]. The present findings might partly explain the 
mechanism of the anabolic action of the intermittent PTH 
administration on bone in vivo, although its precise mecha-
nism remains to be clarified. 
In conclusion, PTH as well as l,25(OH)2D3 stimulated the 
gene expression of IGFBP-5 in osteoblastic UMR-106 cells. 
The transient treatment with PTH, but not l,25(OH)2D3, 
more effectively stimulated this gene expression partly via an 
increase in [Ca2+]i. IGFBP-5 might be partly involved in the 
anabolic action of PTH in bone. 
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